Protokol Etik Penelitian Kesehatan

Yang Mengikutsertakan Manusia Sebagai Subyek

Isilah formulir dibawah ini dengan uraian singkat yang menggambarkan penelitian. (tulis “Tidak
relevan” bila item tidak sesuai/tidak ada dalam penelitian).

A. Judul Penelitian (p-protokol no 1)*

_____________________________________________________________________________
1. Lokasi Penelitian :

_____________________________________________________________________________
Ya Tidak
2. Apakah penelitian ini multi-senter

3. Jika Multi senter apakah sudah mendapatkan persetujuan etik dari

senter/institusi yang lain (lampirkan jika sudah)

B. Identifikasi (p10)

1. Peneliti Utama ( CV dilampirkan)

2. Anggota Peneliti (CV dilampirkan
3. Lembaga Sponsor (Nama Lembaga dan Alamat dilampirkan)

C. Ringkasan ProtokolPenelitian
1. Ringkasan dalam 200 kata, (ditulis dalam bahasa yang mudah difahami oleh “awam” bukan
dokter/profesional kesehatan)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

2. Tuliskan mengapa penelitian ini harus dilakukan, manfaat nya untuk penduduk diwilayah
penelitian ini dilakukan (Negara, wilayah, lokal)- Justifikasi Penelitian (p3) Standar 2/A (Adil)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 2

D. Isu Etik yang mungkin dihadapi

1. Pendapat peneliti tentang isyu etik yang mungkin dihadapi dalam penelitian ini, dan bagaimana
cara menanganinya (p4).
______________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
E. Ringkasan Kajian Pustaka
1. Ringkasan hasil-hasil studi sebelumnya yang sesuai topik penelitian, baik yang sudahmaupun
yang sudah dipublikasikan, termasuk jika ada kajian-kajian pada hewan. Maksimum 1 hal (p5)- G 4,
S?
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

F. Kondisi Lapangan
1. Gambaran singkat tentang lokasi penelitian(p8)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
4. Informasi ketersediaan fasilitas yang tersedia di lapangan yang menunjang penelitian
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
5. Informasi demografis / epidemiologis yang relevan tentang daerah penelitian
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 3

G. Disain Penelitian
1. Tujuan penelitian, hipotesa, pertanyaan penelitian, asumsi dan variabel penelitian (p11)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

6. Deskipsi detil tentang desain penelitian. (p12)

_______________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

7. Bila ujicoba klinis, deskripsikan tentang apakah kelompok treatmen ditentukan secara random,
(termasuk bagaimana metodenya), dan apakah blinded atau terbuka. (Bila bukan ujicoba klinis cukup
tulis: tidak relevan) (p12)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 4

H. Sampling
1. Jumlah subyek yang dibutuhkan dan bagaimana penentuannya secara statistik (p13)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

8. Kriteria partisipan atau subyek dan justifikasi exclude/include-nya. (Guideline 3) (p12)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

9. Sampling kelompok rentan: alasan melibatkan anak anak atau orang dewasa yang tidak mampu
memberikan persetujuan setelah penjelasan, atau kelompok rentan, serta langkah langkah
bagaimana meminimalisir bila terjadi resiko (tulis “tidak relevan” bila penelitian tidak mengikutsertakan kelompok
rentan)(Guidelines 15, 16 and 17) (p15)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 5

I. Intervensi
1. Desripsi dan penjelasan semua intervensi (metode administrasi treatmen, termasuk rute
administrasi, dosis, interval dosis, dan masa treatmen produk yang digunakan (tulis “Tidak relevan”
bila bukan penelitian intervensi) (investigasi dan komparator (p17)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

10. Rencana dan jastifikasi untuk meneruskan atau menghentikan standar terapi/terapi baku selama
penelitian
(p 4 and 5) (p18)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

11. Treatmen/Pengobatan lain yang mungkin diberikan atau diperbolehkan, atau menjadi kontraindikasi,
selama penelitian (p 6) (p19)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

12. Test klinis atau lab atau test lain yang harus dilakukan (p20)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 6

J. Monitoring Penelitian
1. Sampel dari form laporan kasus yang sudah distandarisir, metode pencataran respon teraputik
(deskripsi dan evaluasi metode dan frekuensi pengukuran), prosedur follow-up, dan, bila
mungkin, ukuran yang diusulkan untuk menentukan tingkat kepatuhan subyek yang menerima
treatmen (lihat lampiran) (p17)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

K. Penghentian Penelitian dan Alasannya

1. Aturan atau kriteria kapan subyek bisa diberhentikan dari penelitian atau uji klinis, atau, dalam
hal studi multi senter, kapan sebuah pusat/lembaga di non aktipkan, dan kapan penelitian bisa
dihentikan (tidak lagi dilanjutkan) (p22)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 7

L. Adverse Event dan Komplikasi (Kejadian Yang Tidak Diharapkan)

1. Metode pencatatan dan pelaporan adverse events atau reaksi, dan syarat penanganan
komplikasi (Guideline 4 dan 23)(p23)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

13. Resiko-resiko yang diketahui dari adverse events, termasuk resiko yang terkait dengan masing
masing rencana intervensi, dan terkait dengan obat, vaksin, atau terhadap prosudur yang akan
diuji cobakan (Guideline 4) (p24)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

M. Penanganan Komplikasi (p27)

1. Rencana detil bila ada resiko lebih dari minimal/ luka fisik, membuat rencana detil,
1. Adanya asuransi,
2. Adanya fasilitas pengobatan / biaya pengobatan
3. Kompensasi jika terjadi disabilitas atau kematian (Guideline 14)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 8

N. Manfaat
1. Manfaat penelitian secara pribadi bagi subyek dan bagi yang lainnya (Guideline 4) (p25)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

14. Manfaat penelitian bagi penduduk, termasuk pengetahuan baru yang kemungkinan dihasilkan
oleh penelitian (Guidelines 1 and 4)(p26)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

O. Jaminan Keberlanjutan Manfaat (p28)

1. Kemungkinan keberlanjutan akses bila hasil intervensi menghasilkan manfaat yang signifikan,
15. Modalitas yang tersedia,
16. Pihak pihak yang akan mendapatkan keberlansungan pengobatan, organisasi yang akan
membayar,
17. Berapa lama (Guideline 6)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 9

P. Informed Consent
1. Cara untuk mendapatkan informed consent dan prosudur yang direncanakan untuk
mengkomunikasikan informasi penelitian(Penjelasan Sebelum Persetujuan/PSP) kepada calon
subyek, termasuk nama dan posisi wali bagi yang tidak bisa memberikannya. (Guideline 9)(p30)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

18. Khusus Ibu Hamil: adanya perencanaan untuk memonitor kesehatan ibu dan kesehatan anak
jangka pendek maupun jangka panjang (Guideline 19)(p29)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

Q. Wali (p31)
1. Adanya wali yang berhak bila calon subyek tidak bisa memberikan informed consent (Guidelines 16
and 17)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

19. Adanya orang tua atau wali yang berhak bila anak paham tentang informed consent tapi belum
cukup umur(Guidelines 16 and 17)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 10

R. Bujukan
1. Deskripsi bujukan atau insentif (bahan kontak) bagi calon subyek untuk ikut berpartisipasi,
seperti uang, hadiah, layanan gratis, atau yang lainnya (p32)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

20. Rencana dan prosedur, dan orang yang betanggung jawab untuk menginformasikan bahaya atau
keuntungan peserta, atau tentang riset lain tentang topik yang sama, yang bisa mempengaruhi
keberlansungan keterlibatan subyek dalam penelitian(Guideline 9) (p33)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

21. Perencanaan untuk menginformasikan hasil penelitian pada subyek atau partisipan (p34)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 11

S. Penjagaan Kerahasiaan
1. Proses rekrutmen subyek (misalnya lewat iklan), serta langkah langkah untuk menjaga privasi
dan kerahasiaan selama rekrutmen (Guideline 3) (p16)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

22. Langkah langkah proteksi kerahasiaan data pribadi, dan penghormatan privasi orang, termasuk
kehati-hatian untuk mencegah bocornya rahasia hasil test genetik pada keluarga kecuali atas
izin dari yang bersangkutan (Guidelines 4, 11, 12 and 24) (p 35)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

23. Informasi tentang bagaimana koding; bila ada, untuk identitas subyek, di mana di simpan dan
kapan, bagaimana dan oleh siapa bisa dibuka bila terjadi emergensi (Guidelines 11 and 12) (p36)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

24. Kemungkinan penggunaan lebih jauh dari data personal atau material biologis/BBT(p37)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 12

T. Rencana Analisis
1. Deskripsi tentang rencana analisa statistik, dan kreteria bila atau dalam kondisi bagaimana
akan terjadi penghentian dini keseluruhan penelitian (Guideline 4) (B,S2);
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

U. Monitor Keamanan
1. Rencana untuk memonitor keberlansungan keamanan obat atau intervensi lain yang dilakukan
dalam penelitian atau trial, dan, bila diperlukan, pembentukan komite independen untuk data
dan safety monitoring (Guideline 4) (B,S3,S7);
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

V. Konflik Kepentingan
1. Pengaturan untuk mengatasi konflik finansial atau yang lainnya yang bisa mempengaruhi
keputusan para peneliti atau personil lainya; menginformasikan pada komite lembaga tentang
adanya conflict of interest; komite mengkomunikasikannya ke komite etik dan kemudian
mengkomunikasikan pada para peneliti tentang langkah langkah berikutnya yang harus
dilakukan (Guideline 25) (p42)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 13

W. Manfaat Sosial
1. Untuk penelitian yang dilakukan pada seting sumberdaya lemah, kontribusi yang dilakukan
sponsor untuk capacity building untuk review ilmiah dan etika dan untuk riset-riset kesehatan
di negara tersebut; dan jaminan bahwa tujuan capacity building adalah agar sesuai nilai dan
harapan para partisipan dan komunitas tempat penelitian (Guideline 8) (p43)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

25. Protokol penelitian(dokumen) yang dikirim ke komite etik harus meliputi deskripsi rencana
pelibatan komunitas, dan menunjukkan sumber-sumber yang dialokasikan untuk aktivitas
aktivitas pelibatan tersebut. Dokumen ini menjelaskan apa yang sudah dan yang akan dilakukan,
kapan dan oleh siapa, untuk memastikan bahwa masyarakat dengan jelas terpetakan untuk
memudahkan pelibatan mereka selama riset, untuk memastikan bahwa tujuan riset sesuai
kebutuhan masyarakat dan diterima oleh mereka. Bila perlu masyarakat harus dilibatkan dalam
penyusunan protokol atau dokumen ini (Guideline 7) (p44)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

X. Hak atas Data

1. Terutama bila sponsor adalah industri, kontrak yang menyatakan siapa pemilik hak publiksi
hasil riset, dan kewajiban untuk menyiapkan bersama dan diberikan pada para PI draft laporan
hasil riset (Guideline 24) (B dan H, S1,S7);
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 14

Y. Publikasi
Rencana publikasi hasil pada bidang tertentu(seperti epidemiology, generik, sosiologi).
yang bisa beresiko berlawanan dengan kemaslahatan komunitas, masyarakat, keluarga, etnik tertentu, dan
meminimalisir resiko kemudharatan kelompok ini dengan selalu mempertahankan kerahasiaan data selama
dan setelah penelitian, dan mempublikasi hasil hasil penelitian sedemikian rupa dengan selalu
mempertimbangkan martabat dan kemulyaan mereka (Guideline 4) (p47)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

Bagaimana publikasi bila hasil riset negatip.(Guideline 24) (p46)

________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

Z. Pendanaan
Sumber dan jumlah dana riset; lembaga funding/sponsor, dan deskripsi komitmen finansial sponsor pada
kelembagaan penelitian, pada para peneliti, para subyek riset, dan, bila ada, pada komunitas (Guideline 25) (B,
S2); (p41)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
 15

AA. Komitmen Etik

26. Pernyataan peneliti utama bahwa prinsip-prinsip yang tertuang dalam pedoman ini akan
dipatuhi (lampirkan scan Surat Pernyataan) (p6)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

27. (Track Record) Riwayat usulan review protokol etik sebelumnya dan hasilnya (isi dengan judul
da tanggal penelitian, dan hasil review Komite Etik) (lampirkan Daftar Riwayat Usulan Kaji
Etiknya) (p7)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
28. Pernyataan bahwa bila terdapat bukti adanya pemalsuan data akan ditangani sesuai
peraturan /ketentuan yang berlaku(p48)
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________
________________________________________________________________________________ _____________________________

Tanda tangan Peneliti Utama

______________, tanggal________________

(_______________________________)
 16

BB. Daftar Pustaka

Daftar referensi yang dirujuk dalam protokol (p40)
 17

CC. Lampiran (Upload)

1. CV Peneliti Utama
2. CV Anggota Peneliti
3. Daftar Lembaga Sponsor
4. Surat-surat pernyataan
5. Formulir Laporan kasus/Kuesioner, dll
6. Informed Consent 35 butir

* Urutan nomor pada Protokol Asli CIOMS 2016